(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $26.76
発行日: 15 2月 2024 @ 02:06
リターン: -48.84%
前回のシグナル: 2月 14 - 23:30
前回のシグナル:
リターン: 6.23 %
Live Chart Being Loaded With Signals
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults...
Stats | |
---|---|
本日の出来高 | 1.46M |
平均出来高 | 1.05M |
時価総額 | 823.89M |
EPS | $0 ( 2024-04-25 ) |
次の収益日 | ( $-1.590 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.630 |
ATR14 | $0.0200 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-13 | Greene Barry E | Buy | 168 000 | Stock Option (Right to Buy) |
2024-02-13 | Cook Anne Marie | Buy | 11 250 | Common Stock |
2024-02-13 | Cook Anne Marie | Buy | 22 500 | Stock Option (Right to Buy) |
2024-02-13 | Gault Laura | Buy | 22 500 | Stock Option (Right to Buy) |
2024-02-13 | Gault Laura | Buy | 11 250 | Common Stock |
INSIDER POWER |
---|
92.68 |
Last 97 transactions |
Buy: 1 228 960 | Sell: 86 892 |
ボリューム 相関
SAGE Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
LLNW | -0.876 |
AMGN | -0.859 |
EA | -0.841 |
LAWS | -0.835 |
AHPI | -0.812 |
ASPS | -0.812 |
AUID | -0.811 |
CNET | -0.806 |
ODT | -0.804 |
HCAQ | -0.801 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
SAGE Therapeutics Inc 相関 - 通貨/商品
SAGE Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $86.46M |
総利益: | $84.30M (97.50 %) |
EPS: | $-9.05 |
FY | 2023 |
収益: | $86.46M |
総利益: | $84.30M (97.50 %) |
EPS: | $-9.05 |
FY | 2022 |
収益: | $7.69M |
総利益: | $6.87M (89.42 %) |
EPS: | $-8.49 |
FY | 2021 |
収益: | $6.31M |
総利益: | $5.76M (91.23 %) |
EPS: | $-7.80 |
Financial Reports:
No articles found.
SAGE Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。